Kenvue presents new skin research: Kenvue stock sits 13.61 percent below its high
AD HOC NEWS
Kenvue has presented new scientific evidence for its Neutrogena, Aveeno, and Regaine brands, while its stock currently sits 13.61 percent below its 52-week high. The company reported a 3.00 percent increase in second-quarter revenue to USD 3.96 billion. Analysts generally rate Kenvue as a "Hold" with an average one-year price objective of USD 19.00.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.